Intoxikon, USAEmail: email@example.com
From the desk of
Dr. John Brick,
Journal of Addiction Medicine and Therapy (JAMTS)
Thank you for visiting the Journal of Addiction Medicine and Therapeutic Science (JAMTS) website. Addiction medicine, including new approaches in the diagnosis and treatment of alcohol and drug use disorders and an understanding of the acute and chronic effects of psychoactive drugs is an exponentially growing field. We invite high quality articles in prevention (which we define broadly) so that your work may be communicated rapidly to other scholars, clinicians and researchers through our open access platform.
Articles submitted to JAMTS are assigned to expert reviewers. In most instances, a decision (accept, reject, revise) is made within weeks. Authors can track the progress of their submission through our online tracking process.
In addition, we are revising our editorial board and currently seek scholars with prior experience with the peer-review process to join our board. If you would like to be considered for board membership, please send a letter of interest and complete curriculum vitae to JAMTS at firstname.lastname@example.org.
Research Interest: Psychiatry, Depression, Neuroimaging, Mood Disorders, Anxiety Disorders, Psychosis, Schizophrenia, Anxiety
In 1995 Dr. Blum retired from the University of Texas Health Science Center giving up tenure to enter the world of business and biotechnology. In the second year, acting as manager of 1899 Limited Liability Corporation, his first weight management product grossed in excess of 60 million retail. His company Cyberpharm has launched a weight loss system with Rexall/Showcase which was launched early 1999. Dr. Blum continues to publish research articles, writes books (twelve), lectures, and is actively applying for numerous patents in the field of molecular genetics & nutrition. Dr. Blum is very active as Scientific Director of the Path Medical Foundation and former co-founder and Vice President of the American College of Addictionology and Compulsive Disorders. Dr. Blum is co-founder and Chairman& CSO of Impact Genomics and Managing Partner of IGENE, LLC. He is currently Chief Scientific Officer of G&G HealthCare Services, Inc. and Genomics HealthCare, LLC. His concept of Reward Deficiency Syndrome is being embraced by world leaders in science and is part of the DSM –V, and the DRD2 gene discovery has been confirmed in over 4,000 publications from laboratories all over the world. He serves as Editor –in-Chief Omics Journal of Genetic Syndromes & Gene Therapy, Journal of Addiction Research & Therapy and Genetic Diseases & Genetic Reports, and is currently serving on twelve other prestigious journal’s editorial Boards. He has recently accepted the position of Chief Scientific Officer of Journal operations, Aperito, Publishing House. Currently he has been named Volunteer Full Professor of the Department of Psychiatry & McKnight Brain Institute University of Florida College of Medicine, Gainesville, Florida and Adjunct Research Professor, Human Integrated Services Unit University of Vermont Center for Clinical & Translational Science, College of Medicine, Burlington, VT. He currently serves as neuroscience advisor for Dominion Diagnostics, LLC North Kingstown Rhode Island; G &G Holistic Addiction Treatment center, North Miami Beach Florida and Malibu Beach Recovery Center, Malibu Beach, California. Many consider him as the “Father of Psychiatric Genetics” and “Father of Neuro- Nutrient Therapy”. Dr. Blum received the Life Time Achievement Award from the National Institute of Holistic Addiction Studies 2011, the 2012 Scientific Achievement Award in a Gala Celebrity Event, Miami Beach Florida and Best Abstract Award from the American Society of Anesthesiology and Pain. He and Mark Gold recently signed with Springer as Series editor for Neuroscience of Addiction: A Reference Work which includes four volumes to be published in 2015. Dr. Blum has been notified by Research Gate that is Reputation Score is higher than 97.5% of all scientists in the network to date scoring 40.5. He has also accepted a distinguished appointment of Scientific Advisory Board of NVP's newly formed and funded portfolio company.
Dr. Isabel C. Céspedes is associate professor at the Federal University of São Paulo-UNIFESP (São Paulo, Brazil) where she acts in teaching in morphofunctional area and as a researcher in the search line of neurophysiology of the stress and the addiction. She received her MD and PhD degrees at University of São Paulo (São Paulo, Brazil) in morphofunctional sciences with focus in neuroscience. She conducts research focused on aspects involved in the development of dependence on alcohol and other drugs in humans and animals. She is professor of the Interdisciplinary Graduate Program in Health Sciences. She has studied in humans the correlation between genetic and psychosocial factors in the development of addiction, and in animal the neurological profiles associated with vulnerability to addiction. Also, she has studied the effects of alcohol on the neurodegeneration in decision-making neural areas as well as the positive effects of physical exercises on this degeneration.
Research Interest: My research interest is associated with neurochemical factors and their correlation with environmental stimuli in the stress response, and how these factors are associated with vulnerability to drug abuse.
Research Interest: Drug related death, SIDS, sudden death in all kinds
Research Interest: Psychology & Addiction; Neuroscience & Addiction; Psyhopharmacology & Addiction; Addictive Behaviors; Addiction & Criminology
Research Interest: Alcohol-dependence, insomnia, cognitive-behavior therapy for insomnia, Internet intervention and health effects of underground spaces.
Research Interest: violent behavior and mental disorder; sexual crimes and mental disorder; personality disorders and violent behaviour
Research Interest: Neuropharmacology, genetics, neurologic, psychiatric and neurodegenerative disorders, cell culture, animal models, patients
Research Interest: Benzodiazepine dependence, alcohol dependence, withdrawal symptoms, psychopharmacology,valproate, lithium, lamotrigine, bipolar disorder, adherence, brain imaging, suicide
Research Interest: My personal research interests revolve around the prediction, prevention and treatment of drug abuse in Japan. Another concerns the development and evaluation of group intervention programs for men who are abusive towards their children and their intimate partners.
Research Interest: Anesthesia for gastrointestinal endoscopy, Total intravenous sedation (TIVA), Target controlled infusion (TCI), Sedation for pediatric patients, Anesthesia outside the operating room, Ambulatory anesthesia, Airway management, Acute postoperative pain management
Ray Niaura completed his undergraduate work at McGill
University (Montreal, Quebec), his M.S. and Ph.D. at Rutgers The State
University of New Jersey and postdoctoral clinical internships at Brown
University (Rhode Island, USA). Dr.
Niaura has specialized in behavioral and prevention medicine of addiction
disorders for more than thirty years.
During that time he has held a number of key positions including
Professor of Psychiatry (Brown University), Director of Research, Miriam
Hospital (Rhode Island) and Director of Science and Training, Steven A.
Schroeder Institute for Tobacco Research and Policy Studies (Washington,
DC). He is currently Professor,
Departments of Social and Behavioral Sciences and Epidemiology, New York
University College of Global Publish Health (USA).
Because of his multidisciplinary training and expertise in
behavioral medicine, Dr. Niaura has worked as a consultant to the American
Psychiatric Association, the National Institute of Health/National Institute on
Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, the US
Federal Drug Administration.
Dr. Niaura is the author of more than 400 peer-reviewed
articles, book chapter and monographs and principal or co-investigator on more
than 70 National Institute of Health funded grants. He is a former President of the Society of
Nicotine and Tobacco Research and for many years was involved in
pharmacological treatment approaches to smoking cessation. He has actively contributed to prevention and
treatment research in the Switzerland, Africa and with multiple federal and
other agencies in the US. Dr. Niaura is
a Fellow (Psychopharmacology) of the American Psychological Association and the
recipient of numerous honors and awards in recognition of his contributions to
the field of addiction medicine.
Research Interest: Addiction, Tobacco, Smoking, Dependence,
Treatment, Clinical Trials, Training
1. Schedule of nicotine gum administration and smoking
cessation (Goldstein). Institutional
Research Grant of the American Cancer Society.
Total costs: $7,500. 7/85 - 8/86. Co-Investigator.
2. Hostility and coronary artery disease: The mediating role
of cardiovascular reactivity during behavioral challenge (Ahern). National
Institutes of Health. Total costs: $8,300. 5/86 - 4/88. Co-Investigator.
3. Psychosocial stressors, smoking cessation, and
cardiovascular risk. R01HL32318 (Abrams).
National Heart, Lung, and Blood Institute. Total direct costs:
$465,418. 9/86 - 9/89. Co-Investigator.
4. Self-help smoking cessation and nicotine dependence
(Goldstein). National Cancer Institute.
R03CA44022. Total direct costs: $35,000.
9/86 - 8/87. Co-Investigator.
5. Interventional trial among Type II diabetics with
borderline hypertension (Abrams). Rhode
Island Department of Health. Total direct
costs: $50,000. 4/87 - 3/88.
6. Quality of life in congestive heart failure
(Gorkin). Merck, Sharp & Dohme.
Total direct costs: $108,000. 7/87 - 4/88. Co-Investigator.
7. CAST experimental assessment of suppressor enrollment
(Gorkin). RFANIH-87-H-09-P. Clinical Trials Branch, National Heart, Lung, and
Blood Institute. Total direct costs: $386,706. 1987 - 1990. Co-Investigator.
8. The implications of pulmonary feedback in the prevention
of smoking cessation relapse. American
Lung Association (Niaura). Total direct costs: $34,293. 7/88 - 6/90. Principal
9. Effects of a psychosocial stress manipulation on levels
of lipids and lipoproteins in Cercopithecus Aethiops (Niaura). SO7RR05818. National Institutes of Health. Total costs:
$4,570, 8/88 - 7/89. Principal Investigator.
10. High blood pressure/diabetes treatment program (Abrams).
Rhode Island Department of Health. Total direct costs: $66,000. 9/88 - 9/89.
11. Physician adoption of smoking protocols (Goldstein).
P01CA50087. National Cancer Institute.
Total direct costs: $2,064,000. 7/89 - 6/94.
12. High density lipoprotein cholesterol during smoking
cessation (Niaura). SO7RR05818. National
Institutes of Health. Total direct costs: $7,480. 8/89 - 7/90.
13. Efficacy of clonidine as an aid to smoking cessation
(Goldstein). R01DA05623. National
Institute of Drug Abuse. Total direct costs: $329,103. 9/89 - 9/92. Co-Principal Investigator.
14. Nicotine dependence and smoking relapse (Niaura).
R01HL32318. National Heart, Lung, and
Blood Institute. Total direct costs:
$460,000. 4/91 - 3/94. Principal Investigator.
15. Smoking, alcoholics' reactivity and treatment motivation
(Rohsenow). National Institute of
Alcohol Abuse and Alcoholism. Total
direct costs: $1,336,249. 7/91 -
16. Effects of behavioral challenge on lipids and
lipoproteins (Stoney). National Heart,
Lung, and Blood Institute, 9/91 - 8/94.
Total direct costs: $816,768. Co-Investigator.
17. Smoking's effect on elicited reactions to alcohol cues
among alcoholics. Veterans
Administration Merit Review Award (Monti).
Total direct costs: $287,320.
4/92 - 3/95. Co-Investigator.
18. Coping style, stress responsiveness, and lipids
(Niaura). R01HL46611. National Heart,
Lung, and Blood Institute. Total direct
costs: $813,281. 4/92 - 3/96. Principal
19. Lipid profiles, adiposity, and psychosocial factors
among modernizing Samoans (McGarvey).
Miriam Hospital Foundation. Total direct costs: $14,000. 7/92 - 6/93.
20. Emotions, behaviors, and coronary heart disease
(Engeberetson). Department of Psychiatry
and Human Behavior. Total direct costs: $8,200.
9/92 - 8/93. Co-Investigator.
21. Coping style, stress responsiveness and lipids: Minority
postdoctoral research supplemental award (Niaura). HL46611-01A1S1. National Heart, Lung, and Blood
Institute. Total direct costs:
$107,387. 9/92 - 4/95. Principal Investigator.
22. Coping with depression in smoking cessation
(Brown). National Institute of Drug
Abuse. Total direct costs: $1,450,502. 12/92 - 11/96. Co-Investigator.
23. Coping, exposure & naltrexone treatment with
alcoholics (Monti). National Institute of
Alcohol Abuse and Alcoholism. Total
direct costs: $1,281,433. 6/94 - 5/99.
24. Promoting cancer prevention in primary care
(Goldstein). National Cancer
Institute. Total direct costs:
$1,374,654. 7/94 - 6/99. Co-Principal
25. Effects of a high fat diet on plasma lipoprotein
concentrations (Niaura). Department of Psychiatry
and Human Behavior. Total costs: $13,000.
7/95 - 6/96. Principal
26. Motivation and patch treatment for underserved smokers
(Niaura). National Institute on Drug
Abuse. Total costs: $1,586,476. 7/96 - 6/99.
27. Motivating alcoholics to quit smoking (Abrams). National Institute on Alcoholism and Alcohol
Abuse. Total costs: $3,099,465. 7/96 - 6/01.
28. Matching antidepressant treatment for smoking cessation
(Niaura). National Heart, Lung, &
Blood Institute. Total costs:
$1,548,724. 7/97 - 6/02. Principal Investigator.
29. Coping with depression in smoking cessation
(Brown). National Institute on Drug
Abuse. Total costs: $1,983,952. 7/97 - 6/01.
30. Smoking cessation in teens with comorbid psychopathology
(Brown). National Cancer Institute. Total direct costs: $1,847,469. 9/97 - 9/01.
31. Efficacy of depression skills treatment with alcoholics
(Brown). National Institute on Alcohol
Abuse and Alcoholism. Total costs:
$1,885,712. 7/97 - 6/01. Co-Investigator.
32. HIV and STD intervention research for young men in
prison (Flanigan). Centers for Disease
Control. Total costs: $1,135,841. 9/97 -
33. Naltrexone and nicotine replacement effects on cue
reactivity of smokers (Monti). VA Merit
Review Grant. Total costs: $404,800.
12/97 - 12/01. Co-Investigator.
34. Helping parents in the pediatric ER to quit
smoking. National Cancer Institute. Total costs: $709,018. 4/97 - 3/01.
35. Smoking cessation in the chest pain observation unit
(Bock). Department of Psychiatry
Research Support Grant. Brown University
School of Medicine. Total costs: $12,500.
1998 – 1999. Co-Investigator.
36. Information processing and cue reactivity between
motivated and nonmotivated smokers (Hitsman). American Cancer Society. Total costs: $10,000. 1/98 – 7/99.
37. Moderate exercise to aid smoking cessation in women
(Marcus). National Cancer
Institute. Total costs: $1,284,961. 4/98 – 3/02.
38. Infrastructure support for the Division of Behavioral
and Preventive Medicine (Niaura).
Departmental Research Award.
Total costs: $12,500. 7/98 –
6/99. Principal Investigator.
39. Immunizing against tobacco use in pediatric health care
(Niaura). National Institute on Drug Abuse.
Total costs: $1,468,289. 9/98 -
12/02. Principal Investigator.
40. Smoking cessation in the emergency department (Bock).
American Heart Association. Total costs:
$500,000. 1/99 - 2/01. Co-Investigator.
41. Motivation and patch treatment for HIV+ smokers
(Niaura). National Institute on Drug
Abuse. Total costs: $2,519,197. 1/99 - 12/04.
42. A social cognitive theory of smoking and cessation
(Brown). National Cancer Institute. Total costs: $587,886. 4/99 – 3/02.
43. Psychophysiological and behavioral mechanisms of smoking
(Hutchison). National Cancer Institute,
7/99 – 6/01. Co-Investigator.
44. Motivating parents of kids with asthma to quit smoking
(Borrelli). National Heart, Lung, and
Blood Institute. Total costs:
$1,903,603. 4/99 – 3/03. Co-Investigator.
45. Smoking cessation interventions in the chest pain
observation unit (Bock). National Heart,
Lung, and Blood Institute. Total costs: $1,377,260. 8/99 - 6/03.
46. Adolescent social cognition and cigarette advertising
(Shadel). National Institute on Drug
Abuse. Total costs: $156,191. 9/99 – 8/01.
47. Nicotine dependence: Risk and recovery over generations
(Abrams). National Cancer Institute and National Institute on Drug Abuse
(S.P.O.R.E.). Total costs:
$11,582,454. 10/99 – 9/04. Co-Investigator.
48. Adolescent progression of nicotine dependence
(Niaura). Project 2 of S.P.O.R.E. National Cancer Institute and National
Institute on Drug Abuse. Total costs:
$1,387,924. 10/99 - 9/04. Principal Investigator.
49. Biobehavioral Vulnerability to Early Smoking Relapse
(Brown). National Cancer Institute. Total costs: $362,500. 9/00 – 8/01.
50. Smoking Cessation in Mothers and Other Household Members
of Babies Being Treated in the Special Care Nursery. Robert Wood Johnson Foundation. Total costs: $192,648. 9/00 – 8/02.
51. Smoking cessation among methadone maintained patients
(Stein). 5 R01CA84392-03. National
Cancer Institute. Total costs:
$2,000,000. 6/01-5/05. Co-Investigator.
52. Transdisciplinary cancer control research training grant
(Abrams). National Cancer
Institute. Total costs: $2,671,251. 7/01 – 6/07.
53. Prenatal neuroendocrine mediators of young adult smoking
(Niaura). National Institute of Child
Health and Human Development. Total
costs: $432,103. 6/03-5/05.
54. Sibling Influences on Smoking in Everyday Settings
(Slomkowski). 5R01DA16795. National Institute on Drug Abuse. Total costs: $438,068.
9/03 – 6/08. Co-Investigator
55. Internet and Telephone Treatment for Smoking Cessation
(Graham). 1R01CA104836. National Cancer
Institute. Total Costs: $490,684.
7/04 – 6/09. Co-Investigator.
56. SES, health behaviors and early CVD in Vietnam-era Twins
(McCaffery). R01HL072819. National Heart, Lung and Blood
Institute. Total Costs: $150,000.
6/04 – 5/06. Co-Investigator.
57. Reducing ethnic health disparities: Motivating HIV + Latinos to quit smoking
(Niaura). 1 RO1 DA018079-01. National Institute on Drug Abuse. Total costs:
$2,970,209. 8/05-8/11. Principal Investigator.
58. Tailored Exercise Support for Cardiac Patients. R01HL075561.
(Bock) National Heart, Lung and Blood Institute. Total Costs:
$363,975. 7/04 – 6/08. Co-Investigator.
59. Transdisciplinary Tobacco Use Research Center (TTURC)
Nicotine Dependence: Phenotype,
Endophenotype & Contexts (Niaura). 5P50 CA84719-05. National Cancer Institute. Total costs:
$8,626,255. 8/04-8/10. Principal Investigator.
60. Prenatal Smoking, Fetal Behavior and Infant Withdrawal
(Stroud). R01DA019558. National Institute on Drug Abuse. 6/05 – 5/10.
61. Sex differences in neural circuits of social rejection
stress: A mechanism underlying sex
differences in depression (Stroud).
Brown National Center of Excellence in Women’s Health. Total costs: $20,000. 10/05 – 9/06. Co-Investigator.
62. The Neural Network of Deep Brain Stimulation in OCD
(Greenberg). R01MH073111. National Institute of Mental Health. 9/05 – 8/10.
63. Diabetes Care in American Samoa (McGarvey). R18DK075371.
NIDDK. 9/06-7/10. Co-Investigator.
64. Varenicline versus nicotine replacement for
methadone-maintained smokers (Stein) 5R01CA129226-05 NCI
65. Improving Adherence to Web-Based Cessation Programs: A
Social Network Approach. (Graham) R01 CA 155489-01A1 National Cancer Institute.
07/1/2011 - 06/30/16 Co-Investigator.
66. National Longitudinal Survey of Tobacco Use - Population
Assessment of Tobacco and Health (PATH) National Institute on Drug Abuse/FDA
Center for Tobacco Products HHSN 27120110027C (Abrams site PI) 09/19/2011 –
67. A smoking
cessation trial in HIV-infected patients in South Africa 5R01DA030276-04, Golub
(PI), Niaura (Co-I) 15-SEP-2011 - 31-JUL-2016
68. A Mixed Methods EMA Assessment of Cognition and Behavior
among New ENDS Users. 1R21 DA 036472-01 (Pearson) 09/30/2013 – 08/31/2015
69. Framing messages for teen smoking prevention in primary
care. 5R03CA162839-02 NCI (Mays PI) 19/SEP/2012-31/AUG/2104 Co-Investigator.
70. Neuroimaging approaches to improve prediction of relapse
during smoking cessation 5R21DA031269-03 NIDA (Sweet) 1-JUN-2013-1-JUN-2016
71. Modeling the policy impact of cigarette and smokeless
use on us mortality.
Levy, DT (PI). R01DA036497-03, NIDA,
72. A Comprehensive Approach to Secondary HIV Prevention and
Care Among Positives 3R01DA032217-02S1 NIDA through Johns Hopkins University
(Latkin) 9/15/2012-5/31/2014 Co-Investigator.
71. Center for Evaluation and Coordination of Training and
Research (CECTR) in Tobacco Regulatory
Science. NIH and FDA Center for Tobacco Products (U54) (Rosenthal), WESTAT/Legacy,
09/1/2014 – 08/31/19, Co-PI.
73. Behavioral Activation and Varenicline for Smoking
Cessation in Depressed Smokers (Hitsman), 1 R01 CA184211-01, NCI, 22-SEP-2014 -
74. National Longitudinal Survey of Tobacco Use - Population
Assessment of Tobacco and Health (PATH) National Institute on Drug Abuse/FDA
Center for Tobacco Products HHSN 27120110027C, 04/19/2016 – 03/31/26 (Niaura,
75. Integrating population and behavioral sciences to inform
regulation of e-cigarettes. Individual Allocation from U01FD004319 (FDA), Mays
(PI), Niaura (Co-I) 01/04/2016-12/31/2016.
76. Integrating evidence-based smoking cessation interventions
into lung cancer screening programs: a randomized trial (TAYLOR, KATHRYN-PI),
1R01CA207228, NCI,1-SEP-2016 - 31-AUG-2021 (Co-I).
Research Interest: Epidemiology of suicides and different aspects of alcohol and drug-related problems
Research Interest: Toxicology, Cigarette smoke, Cardiovascular diseases, ERK cell signaling
Research Interest: Dr. Dannon is internationally recognized for his research and publications in the psychiatric treatment of depression, panic disorder, and behavioral addictions, including kleptomania, Internet addiction, and pathological gambling.
Published On: October 24, 2017 | Pages: 032 - 041Abstract View Full Article View DOI: 10.17352/2455-3484.000024
Published On: August 31, 2017 | Pages: 030 - 031Abstract View Full Article View DOI: 10.17352/2455-3484.000023
Published On: July 14, 2017 | Pages: 024 - 029Abstract View Full Article View DOI: 10.17352/2455-3484.000022
Published On: May 12, 2017 | Pages: 016 - 023Abstract View Full Article View DOI: 10.17352/2455-3484.000021
Published On: April 10, 2017 | Pages: 011 - 015Abstract View Full Article View DOI: 10.17352/2455-3484.000020
Published On: March 14, 2017 | Pages: 007 - 010Abstract View Full Article View DOI: 10.17352/2455-3484.000019
Published On: February 22, 2017 | Pages: 001 - 006Abstract View Full Article View DOI: 10.17352/2455-3484.000018
Published On: December 26, 2016 | Pages: 023 - 027Abstract View Full Article View DOI: 10.17352/2455-3484.000017
Published On: December 17, 2016 | Pages: 019 - 022Abstract View Full Article View DOI: 10.17352/2455-3484.000016
Published On: December 02, 2016 | Pages: 013 - 018Abstract View Full Article View DOI: 10.17352/2455-3484.000015
Huazong University of Science and Technology, China
Peertechz Journal of Pediatric Therapy
Cardiometabolic Research Institute, USA
Journal of Cardiovascular Medicine and Cardiology
Sassari University, Italy
Archive of Urological Research
Dr. Rath Research Institute, 1260 Memorex Drive, Santa Clara, USA
Global Journal of Cancer Therapy
Jose Manuel Ramia-Angel
Guadalajara University Hospital , Spain
Journal of Surgery and Surgical Research